4Pickford HA, Swensen SJ, Utz JP. Thoracic cross-sectional imaging of amy- loidosis[J]. A JR Am J Roentgenol, 1997,168(2) :351-355.
5Mahmood S,Palladini G,Sanchorawala V ,et al. Update on treatment of light chain amyloidosis[J]. Haematologica, 2014,99 (2) : 209-221.
6Chu H,Zhao L,Zhang Z, et al. Clinical characteristics of amy|oidosis with isolated respiratory system involvement :a review of 13 cases[J]. Ann Tho- rac Med, 2012,7 ( 4 ) : 243-249.
二级参考文献15
1Merlini G, Bellotti V. Molecular mechanisms of amyloidosis [J]. N Engl J Med, 2003, 349(6):583-596.
2Sipe JD, Benson MD, BuxbaumJN, et al. Amyloid fibril proteinnomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis [J]. Amyloid, 2010, 17(3-4):101-104.
3Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options [J]. J Clin Oncol, 2011, 29 (14): 1924-1933.
4Vrana JA, Gamez JD, Madden B J, et al. Classification of amyloi- dosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens [J]. Blood, 2009, 114(24):4957-4959.
5Klein CJ, Vrana JA, Theis JD, et al. Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue [J]. Arch Neurol, 2011, 68(2): 195-199.
7Lavatelli F, Vrana JA. Proteomic typing of amyloid deposits in systemic amyloidoses [J]. Amyloid, 2011, 18 (4) : 177-182.
8Brambilla F, Lavatelli F, Merlini G, et al. Clinical proteomics for diagnosis and typing of systemic amyloidoses [J]. Proteomics Clin Appl, 2013, 7 ( 1-2 ) : 136-143.
9Mollee P, Renaut P, Gottlieb D, et al. How to diagnose amyloido- sis[J]. Intern Med J, 2014, 44( 1 ):7-17.
10Rodriguez F J, Gamez JD, Vrana JA, et al. Immunoglobulin derived depositions in the nervous system: novel mass spectrometry application for protein characterization in formalin- fixed tissues[J]. Lab Invest, 2008, 88( 10):1024-1037.
